Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 17/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094099 | 0.90 | SCN9A (0.44) | SCN9ACYP3A4CYP2C9SCN5A | |
| SCHEMBL17048544 | 0.89 | SCN9A (0.42) | SCN9ASCN5A | |
| SCHEMBL17048606 | 0.89 | SCN9A (0.42) | SCN9A | |
| SCHEMBL17048525 | 0.88 | SCN9A (0.43) | SCN9ASCN5A | |
| SCHEMBL17056209 | 0.87 | SCN9A (0.35) | SLC22A12SCN9ACYP3A4CYP2C9SCN5A | |
| SCHEMBL14891659 | 0.87 | SCN9A (0.41) | SCN9ACYP3A4CYP2C9SCN5A | |
| SCHEMBL17048608 | 0.87 | SCN9A (0.43) | SLC22A12SCN9A | |
| SCHEMBL1094068 | 0.86 | SCN9A (0.60) | SCN9ACYP3A4CYP2C9SCN5A | |
| SCHEMBL1094993 | 0.85 | SCN9A (0.46) | SLC22A12SCN9A | |
| SCHEMBL320220 | 0.85 | SCN9A (0.40) | SCN9ACYP3A4CYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | SLC22A12 670/4885SCN9A 29/4885CYP3A4 3678/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | SLC22A12 706/4885SCN9A 32/4885CYP3A4 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.